MedTrace Logo

Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation

NCT00487032 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-04-12

No results posted yet for this study

Summary

The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.

Conditions

  • Allergic Rhinitis
  • Tachyphylaxis
  • Rhinitis Medicamentosa

Interventions

DRUG

Oxymetazoline 0.05% w/v

2 squirts in each nostril thrice daily

DRUG

Fluticasone propionate 50 micrograms per actuation

2 Squirts in each nostril twice daily

DRUG

Prazosin hydrochloride

Prazosin 1mg one dose only

DRUG

Placebo to Prazosin

Placebo 1 tablet one dose only

Sponsors & Collaborators

  • Brian J Lipworth

    lead OTHER

Principal Investigators

  • Sriram Vaidyanathan, MRCS, DOHNS · University of Dundee

  • Brian Lipworth, MD, FRCP · University of Dundee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00487032 on ClinicalTrials.gov